BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
BioCryst Pharmaceuticals Enters Oversold Territory (BCRX)
First Week of BCRX December 20th Options Trading
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
These penny stocks offer triple digit returns to investors right now but not many investors are aware of them.
BioCryst Pharmaceuticals files for a mixed securities shelf (NASDAQ:BCRX)
BioCryst Pharmaceuticals (BCRX) has filed a prospectus for a mixed shelf offering, but it is not an offer to sell securities.
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2023.
BioCryst Pharmaceuticals reports Q4 results (NASDAQ:BCRX)
BioCryst Pharmaceuticals reported Q4 financial results, with non-GAAP EPS missing by $0.05 and revenue beating estimates.
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be...
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Launches ORLADEYO® (berotralstat) in Italy
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines...
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
Interesting BCRX Put And Call Options For September 20th
BioCryst Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for BCRX
BioCryst announces preliminary FY23 ORLADEYO net revenue of $325M (NASDAQ:BCRX)
BioCryst Pharmaceuticals expects ORLADEYO net revenue to reach $325 million in 2023, with peak sales forecast at $1 billion and positive cash flow by H2...
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
—ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life over 96 weeks of treatment with...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National...
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower (NASDAQ:INSM)
JP Morgan said it was bullish on Insmed (INSM), Denali (DNLI), Immunocore (IMCR), Crinetics (CRNX), Mirum (MIRM) and BioCryst (BCRX), rating all as overweight. Read more here.
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Launches ORLADEYO® (berotralstat) in Spain
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Spanish Ministry...
BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)
– Additional analysis from APeX-S showed patients who self-reported HAE attack rates at baseline had a median attack rate of 0 attacks per month across...
BioCryst joins Clearside Biomedical for diabetic eye disease
BioCryst Pharmaceuticals (BCRX) and Clearside Biomedical (CLSD) ink a licensing deal to develop a more effective treatment for diabetic macular edema. Read more here.